-
公开(公告)号：US11771711B2
公开(公告)日：2023-10-03
申请号：US17966504
申请日：2022-10-14
IPC分类号： A61K31/675 , A61P35/02 , A61K31/44 , C07D213/85 , C07F9/58
CPC分类号： A61K31/675 , A61K31/44 , A61P35/02 , C07D213/85 , C07F9/58 , C07B2200/13
摘要： The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.
-
公开(公告)号：US11377440B2
公开(公告)日：2022-07-05
申请号：US16652221
申请日：2018-10-04
发明人： David T. Fosbenner , Todd L. Graybill , Jianxing Kang , Bryan W. King , Yunfeng Lan , Lara Kathryn Leister , Mukesh K. Mahajan , John F. Mehlmann , Angel I. Morales-Ramos , George Scott Pesiridis , Joshi M. Ramanjulu , Joseph J. Romano , Stuart Paul Romeril , Mark J. Schulz , Huiqiang Zhou , Junya Qu
IPC分类号： C07D403/14 , C07D401/14 , C07D405/14
摘要： Disclosed are compounds having the formula: (I) wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, R17, Rx, and Ry are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
-
公开(公告)号：US20230101987A1
公开(公告)日：2023-03-30
申请号：US17966504
申请日：2022-10-14
IPC分类号： A61K31/675 , C07F9/58 , C07D213/85 , A61P35/02 , A61K31/44
摘要： The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.
-
-
搜索结果
3 条记录 (耗时 0.015 秒)
